Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cancer Research|May 3, 2008
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft modelLuciana F Macedo, Gauri J Sabnis, Olga G Goloubeva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Therapeutic observations in MCF-7 aromatase xenograftsAngela Brodie, Danijela Jelovac, Luciana Macedo, et al.
Urologic Oncology|December 30, 2008
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerAngela Brodie, Vincent Njar, Luciana Furtado Macedo, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 22, 2005
Model systems: mechanisms involved in the loss of sensitivity to letrozoleAngela Brodie, Danijela Jelovac, Gauri Sabnis, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 19, 2007
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase modelGauri J Sabnis, Luciana Macedo, Olga Goloubeva, et al.
BMC Cancer|June 11, 2011
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsTesfom Abrhale, Angela Brodie, Gauri Sabnis, et al.
Scientific Reports|August 2, 2016
Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes without hormonal effects in the peripheryIstvan Merchenthaler, Malcolm Lane, Gauri Sabnis, et al.
Cancer Research|August 4, 2006
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozoleLuciana F Macedo, Zhiyong Guo, Syreeta L Tilghman, et al.
Molecular Cancer Therapeutics|May 16, 2015
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast CancerRaju Khatri, Preeti Shah, Rupa Guha, et al.
Breast Cancer Research and Treatment|November 28, 2009
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozoleMartin Smollich, Martin Götte, Jeanett Fischgräbe, et al.
Pageof 4